All News Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Real-time Estimate Cboe BZX Other stock markets 01:58:07 2024-04-23 pm EDT			5-day change	1st Jan Change
7.695 ^USD	+5.27%		+4.90%	-22.12%

Apr. 04	British billionaire Joe Lewis fined $5 million by US judge for insider trading	RE
Apr. 04	Multibillionaire Joe Lewis to face US sentencing for insider trading	RE

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

British billionaire Joe Lewis fined $5 million by US judge for insider trading	Apr. 04	RE
Multibillionaire Joe Lewis to face US sentencing for insider trading	Apr. 04	RE
Cantor Fitzgerald Initiates Coverage on Tango Therapeutics With Overweight Rating	Apr. 04	MT
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 01	BU
H.C. Wainwright Adjusts Price Target on Tango Therapeutics to $17 From $16, Keeps Buy Rating	Mar. 20	MT
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	Mar. 18	MT
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	Mar. 18	BU
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Transcript : Tango Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM	Mar. 13
Tango Therapeutics to Participate in Upcoming Investor Conferences	Mar. 06	BU
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	Mar. 05	AQ
Piper Sandler Initiates Tango Therapeutics With Overweight Rating	Feb. 12	MT
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	Jan. 31	AQ
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	Jan. 24	RE
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 05	AQ
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	Jan. 04	PR
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	Jan. 04	AQ
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348	Jan. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

All News

Filters